Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: Identification of a selective inhibitor of hormone-independent breast cancer cells

Bioorganic & Medicinal Chemistry
2015.0

Abstract

We report the synthesis of steroidal 16,17-seco-16,17a-dinitriles and investigate their antitumor cell properties. Compounds were evaluated for anticancer potential by in vitro antiproliferation studies, molecular docking and virtual screening. Several compounds inhibit the growth of breast and prostate cancer cell lines (MCF-7, MDA-MB-231 and PC3), and/or cervical cancer cells (HeLa). Supporting this, molecular docking predicts that steroidal 16,17-seco-16,17a-dinitriles could bind with high affinity to multiple molecular targets of breast and prostate cancer treatment (aromatase, estrogen receptor α, androgen receptor and 17α-hydroxylase) facilitated by D-seco flexibility and nitrile-mediated contacts. Thus, 16,17-seco-16,17a-dinitriles may be useful for the design of inhibitors of multiple steroidogenesis pathways. Strikingly, 10, a 1,4-dien-3-on derivative, displayed selective submicromolar antiproliferative activity against hormone-dependent (MCF-7) and -independent (MDA-MB-231) breast cancer cells (IC50 0.52, 0.11μM, respectively). Ligand-based 3D similarity searches suggest AKR1C, 17β-HSD and/or 3β-HSD subfamilies as responsible for this antiproliferative activity, while fast molecular docking identified AKR1C and ERβ as potential binders-both targets in the treatment of hormone-independent breast cancers.

Knowledge Graph

Similar Paper

Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: Identification of a selective inhibitor of hormone-independent breast cancer cells
Bioorganic & Medicinal Chemistry 2015.0
17(E)-Picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: Antiproliferative activity and molecular docking studies
Bioorganic & Medicinal Chemistry 2013.0
Selective antitumour activity and ERα molecular docking studies of newly synthesized<scp>d</scp>-homo fused steroidal tetrazoles
Med. Chem. Commun. 2012.0
Synthesis of novel 17-(4′-formyl)pyrazolylandrosta-5,16-dienes and their derivatives as potent 17α-hydroxylase/C17,20-lyase inhibitors or antiproliferative agents depending on the substitution pattern of the heteroring
European Journal of Medicinal Chemistry 2016.0
Synthesis, structural analysis and antitumor activity of novel 17α-picolyl and 17(E)-picolinylidene A-modified androstane derivatives
Bioorganic &amp; Medicinal Chemistry 2015.0
Cytotoxicity and gene expression profiles of novel synthesized steroid derivatives as chemotherapeutic anti-breast cancer agents
Bioorganic &amp; Medicinal Chemistry 2011.0
Evaluation of A-ring fused pyridine <scp>d</scp>-modified androstane derivatives for antiproliferative and aldo–keto reductase 1C3 inhibitory activity
MedChemComm 2018.0
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens:  Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model
Journal of Medicinal Chemistry 2005.0
New estrogen receptor antagonists. 3,20-Dihydroxy-19-norpregna-1,3,5(10)-trienes: Synthesis, molecular modeling, and biological evaluation
European Journal of Medicinal Chemistry 2018.0
Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3
Bioorganic &amp; Medicinal Chemistry 2014.0